{"success":true,"data":{"pressRelease":{"id":"18356","rtpr_id":"nNFC71J0F3","ticker":"IMMP","exchange":"NASDAQ","all_tickers":["IMMP","IMM"],"title":"ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP","author":"Newsfile Corp","published_at":"2026-05-04T01:18:22.240Z","article_body":"New York, New York--(Newsfile Corp. - May 3, 2026) - WHY: Rosen Law Firm, a\nglobal investor rights law firm, continues to investigate potential securities\nclaims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from\nallegations that Immutep Ltd. may have issued materially misleading business\ninformation to the investing public.\n\nSO WHAT: If you purchased Immutep Ltd. securities you may be entitled to\ncompensation without payment of any out of pocket fees or costs through a\ncontingency fee arrangement. The Rosen Law Firm is preparing a class action\nseeking recovery of investor losses.\n\nWHAT TO DO NEXT: To join the prospective class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=56430 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nWHAT IS THIS ABOUT: On March 13, 2026, Immutep issued a press release\n\"announcing that the Independent Data Monitoring Committee (IDMC) for the\nTACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in\n1st line non-small cell lung cancer has recommended the discontinuation of the\ntrial following a planned interim futility analysis in accordance with the\nstudy protocol.\" In addition, the press release stated that, \"based on its\nreview of the available safety and efficacy data, the IDMC recommended that\nthe trial be discontinued for futility\" and that, accordingly, \"enrolment in\nthe study will be halted and the Company will implement an orderly wind down\nof the study, including appropriate patient follow up and site close out in\naccordance with regulatory and ethical obligations.\"\n\nOn this news, Immutep's American Depositary Receipt (\"ADR\") price fell $2.28\nper ADR, or 82.6%, to close at $0.48 per ADR on March 13, 2026.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually litigate securities class actions. Be wise\nin selecting counsel. The Rosen Law Firm represents investors throughout the\nglobe, concentrating its practice in securities class actions and shareholder\nderivative litigation. Rosen Law Firm achieved, at that time, the largest ever\nsecurities class action settlement against a Chinese Company. Rosen Law Firm\nwas Ranked No. 1 by ISS Securities Class Action Services for number of\nsecurities class action settlements in 2017. The firm has been ranked in the\ntop 4 each year since 2013 and has recovered hundreds of millions of dollars\nfor investors. In 2019 alone the firm secured over $438 million for investors.\nIn 2020, founding partner Laurence Rosen was named by law360 as a Titan of\nPlaintiffs' Bar. Many of the firm's attorneys have been recognized by\nLawdragon and Super Lawyers.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n-------------------------------\n\nContact Information:\n\nLaurence Rosen, Esq.\nPhillip Kim, Esq.\nThe Rosen Law Firm, P.A.\n275 Madison Avenue, 40th Floor\nNew York, NY 10016\nTel: (212) 686-1060\nToll Free: (866) 767-3653\nFax: (212) 202-3827\ncase@rosenlegal.com\nwww.rosenlegal.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/295695","article_body_html":"","raw_payload":{"data":{"id":"nNFC71J0F3","title":"ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP","author":"Newsfile Corp","ticker":"IMMP","created":"2026-05-04T01:18:22.240Z","tickers":["IMMP","IMM"],"exchange":"NASDAQ","article_body":"New York, New York--(Newsfile Corp. - May 3, 2026) - WHY: Rosen Law Firm, a\nglobal investor rights law firm, continues to investigate potential securities\nclaims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from\nallegations that Immutep Ltd. may have issued materially misleading business\ninformation to the investing public.\n\nSO WHAT: If you purchased Immutep Ltd. securities you may be entitled to\ncompensation without payment of any out of pocket fees or costs through a\ncontingency fee arrangement. The Rosen Law Firm is preparing a class action\nseeking recovery of investor losses.\n\nWHAT TO DO NEXT: To join the prospective class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=56430 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nWHAT IS THIS ABOUT: On March 13, 2026, Immutep issued a press release\n\"announcing that the Independent Data Monitoring Committee (IDMC) for the\nTACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in\n1st line non-small cell lung cancer has recommended the discontinuation of the\ntrial following a planned interim futility analysis in accordance with the\nstudy protocol.\" In addition, the press release stated that, \"based on its\nreview of the available safety and efficacy data, the IDMC recommended that\nthe trial be discontinued for futility\" and that, accordingly, \"enrolment in\nthe study will be halted and the Company will implement an orderly wind down\nof the study, including appropriate patient follow up and site close out in\naccordance with regulatory and ethical obligations.\"\n\nOn this news, Immutep's American Depositary Receipt (\"ADR\") price fell $2.28\nper ADR, or 82.6%, to close at $0.48 per ADR on March 13, 2026.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually litigate securities class actions. Be wise\nin selecting counsel. The Rosen Law Firm represents investors throughout the\nglobe, concentrating its practice in securities class actions and shareholder\nderivative litigation. Rosen Law Firm achieved, at that time, the largest ever\nsecurities class action settlement against a Chinese Company. Rosen Law Firm\nwas Ranked No. 1 by ISS Securities Class Action Services for number of\nsecurities class action settlements in 2017. The firm has been ranked in the\ntop 4 each year since 2013 and has recovered hundreds of millions of dollars\nfor investors. In 2019 alone the firm secured over $438 million for investors.\nIn 2020, founding partner Laurence Rosen was named by law360 as a Titan of\nPlaintiffs' Bar. Many of the firm's attorneys have been recognized by\nLawdragon and Super Lawyers.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n-------------------------------\n\nContact Information:\n\nLaurence Rosen, Esq.\nPhillip Kim, Esq.\nThe Rosen Law Firm, P.A.\n275 Madison Avenue, 40th Floor\nNew York, NY 10016\nTel: (212) 686-1060\nToll Free: (866) 767-3653\nFax: (212) 202-3827\ncase@rosenlegal.com\nwww.rosenlegal.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/295695"},"type":"article","timestamp":"2026-05-04T01:18:22.277514274Z","server_sent_at_ms":1777857502277},"received_at":"2026-05-04T01:18:22.329Z","source_url":"https://www.newsfilecorp.com/release/295695"},"analysis":null,"durationMs":null,"modelName":null}}